Brexit and Life Sciences Companies - Webinar CD/Transcript
Brexit and Life Sciences Companies
Your international drug and device business is at a crossroads known as ‘Brexit’ — the imminent departure of the United Kingdom (U.K.) from the European Union (EU).
Terms of departure are to be negotiated over the coming two years. What will the final outcome look like? Will there be a deal for duty-free movement of goods among nations? Or will punitive tariffs ensue? These are just a few of the questions to which you need answers — ASAP.
FDAnews has invited global drug-and-device expert Michael Burke Esq. to share his crystal ball. As law his firm’s in-house expert on drugs and devices as well as a specialist in cross-border international trade, Mr. Burke is uniquely qualified.
Get set for an information-fest. In 90 fast-paced minutes, Mr. Burke will cover the make-or-break questions, including:
- How might Brexit affect my operation, both short- and long-term?
- Should I consider moving operations into or out of the U.K?
- What are the advantages and disadvantages of operating in Ireland?
- With the European Medicines Agency (EMA) moving out of the UK, how will marketing authorization in both the EU and U.K. be affected?